PTC Therapeutics, Inc. cash flow to debt ratio of 26.27% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

PTC Therapeutics, Inc.'s free cash flow has increased 326.00% from $-181.94M last year to $411.18M, signaling increasing performance

PTC Therapeutics, Inc.'s debt to equity ratio is -3.33, signaling that the company spent its equity and risk bankruptcy.

PTC Therapeutics, Inc.'s debt has increased relative to shareholder equity from -2.25 last year to -3.33 today, signaling weakened financials

PTC Therapeutics, Inc. has a net debt to EBITDA ratio of 0.86x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

PTC Therapeutics, Inc.'s interest coverage ratio is 0.70, which means that the company struggles to meet interest obligations, signaling financial risk.

PTC Therapeutics, Inc.'s profit margin was -45.03% last year and is -9.17% this year, signaling increasing performance

PTC Therapeutics, Inc.'s short-term assets of $2.27B exceed its short-term liabilities of $968.43M

PTC Therapeutics, Inc.'s return on assets of -3.30% is lower than the 5.00% threshold, indicating inefficient asset utilization

PTC Therapeutics, Inc.'s return on equity of 57.10%, is higher than 15.00%, indicating good performance

PTC Therapeutics, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

PTC Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

PTC Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

PTC Therapeutics, Inc. has a free cash flow yield of 7.52%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

PTC Therapeutics, Inc.'s yearly earnings has increased 287.90% since last year from $-363.30M to $682.64M, signaling increasing performance

PTC Therapeutics, Inc.'s yearly revenue has increased 114.51% since last year from $806.78M to $1.73B, signaling increasing performance

ROIC 5.66% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

PTC Therapeutics, Inc.'s 3-year revenue CAGR of 35.30% is positive, indicating growing revenue over the past 3 years

PTC Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

PTC Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

PTC Therapeutics, Inc. has insufficient data to evaluate this check.

PTC Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PTC Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

PTC Therapeutics, Inc. has an EV/EBITDA ratio of 7.02x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

PTC Therapeutics, Inc. has insufficient data to evaluate this check.

PTC Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

PTC Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

PTC Therapeutics, Inc. has a price-to-sales ratio of 4.73x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue